Paclitaxel oral solution versus paclitaxel injection as a second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial.

被引：0
|
作者：
Li, Jin
Huang, Mingzhu
Deng, Ting
Bai, Yuxian
Liu, Tianshu
Pan, Yueyin
Yu, Junyan
Pan, Hongming
Xu, Huiting
Wang, Jufeng
Ye, Feng
Wang, Junye
Wu, Jinsheng
Cang, Shundong
Chen, Kehe
Zhang, Jun
Zhang, Jingdong
Ling, Yang
Liu, Yin
Qin, Shukui
机构：
[1] Shanghai GoBroad Canc Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[4] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[5] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[6] Anhui Prov Hosp, Hefei, Peoples R China
[7] Heping Hosp, Changzhi Med Coll, Changzhi, Peoples R China
[8] Zhejiang Univ, Sir RunRun Shaw Hosp, Sch Med, Hangzhou, Peoples R China
[9] Hubei Canc Hosp, Wuhan, Peoples R China
[10] Henan Canc Hosp, Zhengzhou, Peoples R China
[11] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
[12] Jining Med Univ, Affiliated Hosp, Jining, Peoples R China
[13] Hainan Med Univ, Affiliated Hosp 1, Haikou, Peoples R China
[14] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China
[15] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[16] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China
[17] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[18] Changzhou Canc Hosp, Changzhou, Peoples R China
[19] Haihe Biopharm Co Ltd, Shanghai, Peoples R China
[20] Nanjing Tianyinshan Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.442
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Paclitaxel oral solution versus paclitaxel injection as second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial
    Li, Jin
    Huang, Mingzhu
    Deng, Ting
    Bai, Yuxian
    Liu, Tianshu
    Pan, Yueyin
    Yu, Junyan
    Pan, Hongming
    Xu, Huiting
    Wang, Jufeng
    Ye, Feng
    Wang, Junye
    Wu, Jinsheng
    Cang, Shundong
    Chen, Kehe
    Zhang, Jun
    Zhang, Jingdong
    Ling, Yang
    Liu, Yin
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
    Shitara, Kohei
    Takashima, Atsuo
    Fujitani, Kazumasa
    Koeda, Keisuke
    Hara, Hiroki
    Nakayama, Norisuke
    Hironaka, Shuichi
    Nishikawa, Kazuhiro
    Makari, Yoichi
    Amagai, Kenji
    Ueda, Shinya
    Yoshida, Kazuhiro
    Shimodaira, Hideki
    Nishina, Tomohiro
    Tsuda, Masahiro
    Kurokawa, Yukinori
    Tamura, Takao
    Sasaki, Yasutsuna
    Morita, Satoshi
    Koizumi, Wasaburo
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (04): : 277 - 287
  • [3] Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial
    Li, Rong
    Zhang, Hongping
    Li, Qingshui
    Yuan, Guangwen
    Zhou, Yanjie
    Yin, Rutie
    Wang, He
    Wang, Chunyan
    Huang, Yi
    Wang, Wei
    Yan, Xiaojian
    Wu, Lingying
    Zhou, Qi
    JOURNAL OF THE NATIONAL CANCER CENTER, 2024, 4 (02): : 135 - 141
  • [4] Randomized Phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancer
    Fushida, Sachio
    Kaji, Masahide
    Oyama, Katsunobu
    Hirono, Yasuo
    Nezuka, Hideaki
    Takeda, Toshiya
    Tsukada, Tomoya
    Fujimoto, Daisuke
    Ohyama, Shigekazu
    Fujimura, Takashi
    Ohta, Tetsuo
    ONCOTARGETS AND THERAPY, 2015, 8 : 939 - 941
  • [5] Paclitaxel plus valproic acid versus paclitaxel alone as second or third line therapy for advanced gastric cancer: a randomized phase 2 trial
    Kinoshita, J.
    Fushida, S.
    Kaji, M.
    Oyama, K.
    Hirono, Y.
    Nezuka, H.
    Takeda, T.
    Tsukada, T.
    Ohyama, S.
    Fujimura, T.
    Ohta, T.
    ANNALS OF ONCOLOGY, 2016, 27 : 82 - 82
  • [6] Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial.
    Wang, Fenghua
    Ren, Chao
    Xu, Jianying
    Wang, Zhiqiang
    He, Ming-ming
    Qiu, Miaozhen
    Jin, Ying
    Luo, Huiyan
    Wang, Feng
    Li, Yuhong
    Tan, Qiong
    Zhang, Rong
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] A Randomized, Open-Label Clinical Trial of Tasisulam Sodium Versus Paclitaxel as Second-Line Treatment in Patients With Metastatic Melanoma
    Hamid, Omid
    Ilaria, Robert, Jr.
    Garbe, Claus
    Wolter, Pascal
    Maio, Michele
    Hutson, Thomas E.
    Arance, Ana
    Lorigan, Paul
    Lee, Jeeyun
    Hauschild, Axel
    Mohr, Peter
    Hahka-Kemppinen, Marjo
    Kaiser, Christopher
    Turner, P. Kellie
    Conti, Ilaria
    Grob, Jean-Jacques
    CANCER, 2014, 120 (13) : 2016 - 2024
  • [8] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study
    Ohtsu, A.
    Tabernero, J.
    Bang, Y. -J.
    Fuchs, C.
    Sun, L.
    Wang, Z.
    Csiki, I.
    Koshiji, M.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2015, 26
  • [9] Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer
    McMeekin, Scott
    Dizon, Don
    Barter, James
    Scambia, Giovanni
    Manzyuk, Lyudmila
    Lisyanskaya, Alla
    Oaknin, Ana
    Ringuette, Sarah
    Mukhopadhyay, Pralay
    Rosenberg, Julie
    Vergote, Ignace
    GYNECOLOGIC ONCOLOGY, 2015, 138 (01) : 18 - 23
  • [10] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
    Robert, Nicholas J.
    Saleh, Mansoor N.
    Paul, Devchand
    Generali, Daniele
    Gressot, Laurent
    Copur, Mehmet S.
    Brufsky, Adam M.
    Minton, Susan E.
    Giguere, Jeffrey K.
    Smith, John W., II
    Richards, Paul D.
    Gernhardt, Diana
    Huang, Xin
    Liau, Katherine F.
    Kern, Kenneth A.
    Davis, John
    CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92
12345